New therapeutic options for metabolic‐associated steatotic liver disease
Open Access
- 27 August 2026
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (11) , 3770-3777
Abstract
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and malignancies. The pathogenesis of MASLD stems from a multifactorial interaction among genetic susceptibility, epigenetic modifications and environmental factors, which collectively impair systemic metabolic homeostasis. Current management relies on a combination of lifestyle modification and pharmacotherapy. Resmetirom is the first drug registrated for the treatment of adults with MASLD and moderate to advances fibrosis. Over the next decade, multiple promising pharmacotherapies with diverse mechanisms of action and routes of administration are expected to become available for the treatment of MASLD. This narrative review provides an overview of the evolving pharmacological therapeutic landscape for MASLD, with a focus on novel therapeutic agents in late‐stage clinical development as THR‐β Agonists, GLP‐1 Receptor Agonists, Dual GLP‐1/ GIP Agonists, Glucagon/GLP‐1 Dual Agonists, FGF‐21 Analogues, Pan‐PPAR Agonists and FASN Inhibitors. Based on the differences in mechanisms of actions and specific side effects of these therapies, the characteristics of patients with MASLD should be taken into account in the decision which pharmacologic treatment should be initiated in an individual patient. Also, combining different therapies could be beneficial since this appears to possess complementary mechanisms.Keywords
This publication has 17 references indexed in Scilit:
- Efruxifermin in Compensated Liver Cirrhosis Caused by MASHNew England Journal of Medicine, 2025
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated SteatohepatitisNew England Journal of Medicine, 2025
- GLP‐1RA‐induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025
- Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver FibrosisNew England Journal of Medicine, 2024
- A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisNew England Journal of Medicine, 2024
- FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyondJournal of Hepatology, 2024
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver FibrosisNew England Journal of Medicine, 2024
- Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASHNew England Journal of Medicine, 2023
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASHNew England Journal of Medicine, 2021
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020